page.php

PRECISION TREATMENT

Precision treatment is an opportunity to curb the overuse of broad-spectrum antibiotics that is fuelling the development of drug-resistance, and at the same time offer a more efficient, and gentle treatment to many patients.

 

In order to prescribe precise medicine, doctors need precise diagnosis of the bad bacteria at play. That requires cultivation of a given bacteria in a lab, which today takes at least 48 hours. Today, antibiotics are often administered without a proper diagnosis. Precise diagnosis for precision medicine is an unfolding opportunity.

NEW TOOLBOX
This opportunity covers a range of tools allowing doctors to identify the exact type of bacteria during the time of consultation and therefore to prescribe narrow spectrum antibiotics. New diagnostic tools will facilitate the advance of a ‘one bug, one drug’ approach to antibiotic develop- ment and to the treatment of patients. Hopefully, these new tests will allow bacteria to be identified directly from clinical samples (e.g. blood), speeding up diagnosis and enabling the most appropriate antibiotic to be administered within hours. For tuberculosis, the time to diagnosis of multidrug resistance has been cut from several months to two hours by a game-changing molecular test.

New diagnostic tools will enable doctors to prescribe the relevant narrow spectrum antibiotics, whereby reducing the use of broad-spectrum antibiotics. The narrow spectrum antibiotics will not kill as many of the normal microorganisms in the body as the broad-spectrum antibiotics and thereby reduce side effects. In addition, it will lead to less resistance by putting pressure on fewer types of bacteria.

The new screening approach will enable highly specific antibiotics to be designed, accelerating the race to overcome resistance and creating a market for new treatments. New tools will allow doctors to undertake rapid diagnosis. In developing countries, with low levels of lab capacity, such tools can mean leapfrogging into higher quality health care.

PROBIOTICS
Precise medication is not limited to narrow spectrum antibiotics, but also concerns the so-called probiotics. Probiotics are living bacteria and yeasts, delivered in food and drinks or as purified supplements, which are intended to help the body fend off bad bacteria and prevent infections or other problems. WHO defines probiotics as live microorganisms which when administered in adequate amount confer a health benefit. Exactly how probiotics work remains to be fully understood.

Probiotics are given to both treat and prevent diseases and are situated at the overlap between scientific medicine and alternative medicine. Research shows that probiotics may substitute antibiotics in a number of cases and allow for more targeted treatment.

The new technologies in development promise accurate diagnostics at a much accelerated pace compared to today. Yet, they still need to be reduced in size and they need to be affordable also in low resource settings, and that takes investment and innovation. However, developing the diagnostic tools to allow for fast and precise targeting of antibiotic therapy will not only save lives and save patients a lot of discomfort, it can also limit the development of antibiotic resistance.

Prescribing more precise dosages of drugs will result in faster treatments and fewer sick days for the patients, lowering the overall cost for the health system and slowing down the development of resistance.

Key Numbers

1

Trillion US Dollars lost value every year from low recycling rates.

90

percent of phosphorus and 40% of ammonia load can be removed from sludge dewatering liquid.

560

Million US Dollars added value annual with nutrient cycling for Finland.

Solutions for this Opportunity

ANTIBODIES TO DELIVER ANTIBIOTICS PRECISELY

Genentech is testing a new precision drug therapy in which only the targeted bacteria are exposed to the antibiotic.
Location: Global See this solution

ANTIBIOTICS WITH “ON-OFF SWITCH”

Scientists at the University of Groningen are testing an antibiotic that stays inactive when it is in non-infected areas of the body.
Location: Global See this solution

RAPID DIAGNOSIS TEST

The University of Fribourg and INSERM have developed a rapid diagnostic test for multi-resistance to broad-spectrum antibiotics.
Location: Global See this solution

TESTS ON INDIVIDUAL BACTERIAL RESPONSES

Research from the Seoul National University shows that response from individual bacterial cells to antibiotics can provide rapid diagnosis.
Location: Global See this solution

QUICK SCREENING OF BACTERIAL RESPONSES

Scientists at the University of Lausanne have found a way to quantitatively screen bacterial responses to antibiotics.
Location: Global See this solution

BACTERIA-ATTACKING VIRUSES

AmpliPhi and the University of Adelaide experiment with bacteriophages, viruses that infect only bacteria, to battle staphylococcus.
Location: Global See this solution

BATTLING SUPERBUGS WITH PROTEINS

GangaGen has developed a protein (P128) to prevent and treat infections caused by the ‘super- bug’ MRSA.
Location: Global See this solution

DNA TESTS FOR QUICK DIAGNOSIS

A project from UCSF and California Initiative to Advance Precision Medicine use DNA sequencing tests to diagnose acute infections.
Location: Global See this solution



SURVEY FINDINGS

AN OPPORTUNITY THAT DIVIDES THE HDI COUNTRIES

Precision treatment makes it into the top ve of all opportunities worldwide. It is also the highest ranked opportunity to address the risk of loss of lifesaving medicine.

NOT ON TOP OF THE LIST IN CHINA

To keep antibiotics working in order to treat infections, precision treatment has been assessed as one of the top opportunities of all among the respondents in Europe. By contrast, respondents in China do not see much potential in this opportunity, as they rate it among the lowest of all opportunities. Respondents in South America have expressed confidence in this opportunity to have great benefits for society, but political will power to pursue it is perceived to be missing in the region.

MIXED PERCEPTIONS

It is the one of the favourite opportunities among the very high HDI countries whereas for high HDI countries it is ranked as one of the lowest on the opportunity list. Across age groups it is one of the least preferred by respondents below the age of 30 and it is the second most favoured opportunity for respondents at the age of 50 and above.

Among business respondents, the finance sector sees itself as the most affected, but surprisingly, results show that the same sector is not very likely to pursue new business opportunities within precision treatment. The only other business sector that perceives itself to be affected by this opportunity is the ‘other business sector’, which may be explained by the fact that the pharmaceutical industry is part of this sector category.

NUMBER 5 ON THE OPPORTUNITY RANKING

Regenerative Ocean Economy_Ranking

THE ECONOMIC CAPACITY, TECHNOLOGICAL CAPACITY, AND THE POLITICAL WILL POWER TO PURSUE THIS OPPORTUNITY ACROSS NINE REGIONS

Capacity to puruse_Regenerative Ocean

BENEFITS AND CAPACITY

Perceived benefits from pursuing this opportunity (x), and capacity to do so (y), World and geographic regions. Scale goes from -10 to +10.

GOR_SocietyCapacity_Regenerative Ocean Economy


Learn more about the Global Opportunity Report 2017

Learn more

Download the full Global Opportunity 2017 Report here!

Download the report

Contact

General Enquiries

Press Information

  • For press information, please see our: Press page

Newsletter

  • Sign up here to receive the monthly newsletter from the Global Opportunity Network
© 2013 - 2018 - DNV GL, Veritasveien 1, 1363 Høvik, Norway